EQUASENS GROUP

H1 2023 revenue: up 9% to €112.62m

Villers-lès-Nancy, 3 August 2023 - 6:00 p.m. (CET)

PRESS RELEASE

H1 2023 revenue:
up 9% to €112.62m

• Growth by all Divisions, with the exception of FINTECH, which nonetheless benefited from an upturn in Q2.
• Effects of the French Digital Healthcare investment programme (Ségur du Numérique en Santé)
  • The Group is continuing to install solutions qualifying for the Ségur French Digital Healthcare investment programme: €2m at 30 June 2023.
  • Sales revenues from the recurring portion of the Ségur programme: €0.6m.

(€m)	H1 2022	H1 2023	Change 2023 / 2022
Q1	49.36	56.25	+14% (*)
Q2	54.21	56.37	+4%
H1	103.57	112.62	9%

⁽*⁾ Strong growth in Q1 reflecting a favourable comparison base (restructuring of the electronic labelling activity).

As a reminder, to streamline business operations, organisational changes were implemented in H1 involving business transfers between Divisions:

• After buying out the minority interests, MULTIMEDS (Ireland) and I-MEDS (Germany) were transferred to the PHARMAGEST Division (Compliance segment) and CAREMEDS (United Kingdom) joined the AXIGATE LINK Division (Nursing Home segment);
• The ICT company developing MEDILINK, a solution for health centres and regional health professional communities, has joined forces with the MEDICAL SOLUTIONS Division to expand PROKOV EDITIONS' range.

Plus recent acquisitions:

• ATOOPHARM joined the PHARMAGEST Division,
• SPEECH2SENSE and PRATILOG are now part of the MEDICAL SOLUTIONS Division.

Consolidated for the first time in Q2, revenue generated by these entities was not material at 30 June 2023.

H1 2023 business highlights

• The PHARMAGEST Division  reported sales of €83.7m, up 9% from H1 2022
  • While growth by the PHARMAGEST Division was more subdued in Q2, revenue remained strong at €83.7m at 30 June 2023, up from €76.7m in 2022.
  • The growth drivers remained unchanged, with strong momentum in the electronic labelling market and, in Italy, new pharmacy software solutions.
  • This Division accounted for 74% of Equasens Group's total revenue.

• The AXIGATE LINK Division recorded revenue of €14.9m, up 6% from H1 2022, driven in particular by the long-standing Nursing Homes and Home Hospital business.
  • This Division accounted for 13% of Equasens Group's total revenue.

• The E-CONNECT Division had revenue of €8.1m, up 10% from H1 2022.
  • Q2’s excellent performance (+17% to €4.1m) confirmed the benefits of the new industrial strategy of diversifying production sourcing enabling the Division to respond more rapidly to market needs.
  • This Division accounted for 7% of Equasens Group's total revenue.